

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

Patient/carer organisation statement template

Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS.

Patients and patient advocates can provide a unique perspective on the technology, which is not typically available from the published literature.

To help you give your views, we have provided a template. The questions are there as prompts to guide you. You do not have to answer every question. Please do not exceed the 8-page limit.

About you

Your name:

Name of your organisation: [Lifeblood: The Thrombosis Charity](#)

Are you (tick all that apply):

- a patient with the condition for which NICE is considering this technology?
- a carer of a patient with the condition for which NICE is considering this technology?
- an employee of a patient organisation that represents patients with the condition for which NICE is considering the technology? If so, give your position in the organisation where appropriate (e.g. policy officer, trustee, member, etc)
- other? (please specify)

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition?

1. Advantages

(a) Please list the specific aspect(s) of the condition that you expect the technology to help with. For each aspect you list please describe, if possible, what difference you expect the technology to make.

This technology will simplify the administration of anticoagulation enormously in that it is a once a day tablet which needs no monitoring from the day of diagnosis.

It also has the advantage of less contraindications when taken in conjunction with other drugs and its efficacy is not affected by food interactions as with current treatment

(b) Please list any short-term and/or long-term benefits that patients expect to gain from using the technology. These might include the effect of the technology on:

- the course and/or outcome of the condition
- physical symptoms
- pain
- level of disability
- mental health
- quality of life (lifestyle, work, social functioning etc.)
- other quality of life issues not listed above
- other people (for example family, friends, employers)
- other issues not listed above.

This technology has the potential to significantly improve the quality of life of the patient being treated by removing the need for constant monitoring, frequent blood tests and, many visits to the Anticoagulation Clinic thus making day-to-day life far less arduous than it can be at present.

At present patients often state they have problems taking time off work to attend frequent A/C Clinic visits and this technology would remove that problem.

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

[This technology would also be beneficial to those individuals who cannot tolerate the current standard treatments.](#)

What do patients and/or carers consider to be the advantages and disadvantages of the technology for the condition? (continued)

2. Disadvantages

Please list any problems with or concerns you have about the technology.

Disadvantages might include:

- aspects of the condition that the technology cannot help with or might make worse.
- difficulties in taking or using the technology
- side effects (please describe which side effects patients might be willing to accept or tolerate and which would be difficult to accept or tolerate)
- impact on others (for example family, friends, employers)
- financial impact on the patient and/or their family (for example cost of travel needed to access the technology, or the cost of paying a carer).

[None](#)

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

3. Are there differences in opinion between patients about the usefulness or otherwise of this technology? If so, please describe them.

[No](#)

4. Are there any groups of patients who might benefit **more** from the technology than others? Are there any groups of patients who might benefit **less** from the technology than others?

[Patients who cannot take the current standard therapy would benefit more from this technology as it would mean they would have access to an alternative therapy instead of having no treatment available.](#)

[There are no patients groups that would benefit less from this technology](#)

Comparing the technology with alternative available treatments or technologies

NICE is interested in your views on how the technology compares with with existing treatments for this condition in the UK.

(i) Please list any current standard practice (alternatives if any) used in the UK.

[Low molecular weight and unfractionated heparins and warfarin](#)

(ii) If you think that the new technology has any **advantages** for patients over other current standard practice, please describe them. Advantages might include:

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

- improvement in the condition overall
- improvement in certain aspects of the condition
- ease of use (for example tablets rather than injection)
- where the technology has to be used (for example at home rather than in hospital)
- side effects (please describe nature and number of problems, frequency, duration, severity etc.)

[A definite advantage of this new technology is its ease of use and the lesser impact it has on a patients day-to-day life](#)

(iii) If you think that the new technology has any **disadvantages** for patients compared with current standard practice, please describe them. Disadvantages might include:

- worsening of the condition overall
- worsening of specific aspects of the condition
- difficulty in use (for example injection rather than tablets)
- where the technology has to be used (for example in hospital rather than at home)
- side effects (for example nature or number of problems, how often, for how long, how severe).

[None](#)

Research evidence on patient or carer views of the technology

If you are familiar with the evidence base for the technology, please comment on whether patients' experience of using the technology as part of their routine NHS care reflects that observed under clinical trial conditions.

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

[n/a](#)

Are there any adverse effects that were not apparent in the clinical trials but have come to light since, during routine NHS care?

[n/a](#)

Are you aware of any research carried out on patient or carer views of the condition or existing treatments that is relevant to an appraisal of this technology? If yes, please provide references to the relevant studies.

[n/a](#)

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

Availability of this technology to patients in the NHS

What key differences, if any, would it make to patients and/or carers if this technology was made available on the NHS?

[Ease of use and lack of interaction with other drugs would make this technology beneficial for patients](#)

What implications would it have for patients and/or carers if the technology was **not** made available to patients on the NHS?

[Some patients would continue to need injections and others would continue to have no therapy available at all due to reactions to the current treatments](#)

Are there groups of patients that have difficulties using the technology?

[No](#)

Rivaroxaban for the treatment and secondary prevention of venous thromboembolism

Other Issues

Please include here any other issues you would like the Appraisal Committee to consider when appraising this technology.

None